— Achieve Life Sciences (NASDAQ: ACHV) reported Q4 2019 net loss of $3.2 million, or $0.30 per share, compared to a loss of $3.6 million, or $0.55 per share, last year.
— Total operating expenses were $3.2 million.
— At December 31, 2019, cash, cash equivalents and restricted cash was $16.7 million.
— Achieve Life Sciences completed a meeting with the US FDA to finalize the Phase 3 cytisinicline clinical development program.
— The company established an agreement with the FreeMind Group to assist in securing non-dilutive funding to evaluate cytisinicline in vapers and e-cigarette users.
— The company closed an underwritten public offering for gross proceeds of $13.8 million, before underwriting discounts and commissions and offering expenses.
— ACHV shares were up 12.7% in premarket hours on Friday.
The cloud computing market witnessed accelerated growth in the last couple of years, as enterprises across the world shifted their digital assets to cloud for ensuring safety and enhancing data
Dollar Tree (DLTR) vs. Dollar General (DG): How did the third quarter turn out for these discount retailers?
In times of high inflation and economic uncertainty, consumers tend to turn to discount retailers in search of more value. The two leading discount retailers Dollar Tree Inc. (NASDAQ: DLTR)
The retail environment has witnessed many changes in customers’ shopping behavior lately, especially after the COVID outbreak. With inflation putting pressure on personal finances, there appears to be a new